Catalyst Pharmaceuticals (NASDAQ:CPRX) Hits New 52-Week High at $17.72

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) reached a new 52-week high on Tuesday . The stock traded as high as $17.72 and last traded at $17.63, with a volume of 358261 shares. The stock had previously closed at $17.00.

Analyst Upgrades and Downgrades

CPRX has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $26.00 price target on shares of Catalyst Pharmaceuticals in a research note on Monday, June 3rd. StockNews.com upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 7th. Finally, Oppenheimer reiterated an “outperform” rating and set a $29.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, June 6th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $27.80.

Catalyst Pharmaceuticals Price Performance

The business has a 50-day moving average of $15.94 and a 200 day moving average of $15.41. The company has a market cap of $2.05 billion, a PE ratio of 32.80 and a beta of 0.71.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.31. Catalyst Pharmaceuticals had a return on equity of 25.08% and a net margin of 15.83%. The business had revenue of $98.51 million during the quarter, compared to analyst estimates of $97.24 million. On average, equities analysts predict that Catalyst Pharmaceuticals, Inc. will post 1.63 EPS for the current fiscal year.

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 80,000 shares of the company’s stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $16.16, for a total value of $1,292,800.00. Following the completion of the transaction, the insider now owns 51,391 shares of the company’s stock, valued at $830,478.56. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Catalyst Pharmaceuticals news, CEO Richard J. Daly sold 17,323 shares of the firm’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $15.97, for a total transaction of $276,648.31. Following the completion of the transaction, the chief executive officer now owns 234,824 shares in the company, valued at approximately $3,750,139.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gary Ingenito sold 80,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $16.16, for a total value of $1,292,800.00. Following the transaction, the insider now owns 51,391 shares of the company’s stock, valued at approximately $830,478.56. The disclosure for this sale can be found here. Insiders sold a total of 110,197 shares of company stock valued at $1,777,560 over the last 90 days. Company insiders own 11.00% of the company’s stock.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Parkside Financial Bank & Trust bought a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at approximately $31,000. GAMMA Investing LLC boosted its holdings in Catalyst Pharmaceuticals by 72.9% during the 1st quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 819 shares during the period. CWM LLC grew its position in Catalyst Pharmaceuticals by 686.5% in the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 3,549 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Catalyst Pharmaceuticals by 306.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 5,079 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 3,829 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Catalyst Pharmaceuticals by 84.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,184 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 2,833 shares during the period. 79.22% of the stock is owned by institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.